期刊
BLOOD
卷 115, 期 2, 页码 418-429出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-12-196840
关键词
-
类别
资金
- National Institutes of Health [1R15CA125682-01]
- Illinois William E. McElroy Foundation
- SIUSOM Excellence in Medicine
- Department of Defense [BC07331]
The concept of inflammation-induced lymphangiogenesis (ie, formation of new lymphatic vessels) has long been recognized, but the molecular mechanisms remained largely unknown. The 2 primary mediators of lymphangiogenesis are vascular endothelial growth factor receptor-3 (VEGFR-3) and Prox1. The key factors that regulate inflammation-induced transcription are members of the nuclear factor-kappaB (NF-kappa B) family; however, the role of NF-kappa B in regulation of lymphatic-specific genes has not been defined. Here, we identified VEGFR-3 and Prox1 as downstream targets of the NF-kappa B pathway. In vivo time-course analysis of inflammation-induced lymphangiogenesis showed activation of NF-kappa B followed by sequential up-regulation of Prox1 and VEGFR-3 that preceded lymphangiogenesis by 4 and 2 days, respectively. Activation of NF-kappa B by inflammatory stimuli also elevated Prox1 and VEGFR-3 expression in cultured lymphatic endothelial cells, resulting in increased proliferation and migration. We also show that Prox1 synergizes with the p50 of NF-kappa B to control VEGFR-3 expression. Collectively, our findings suggest that induction of the NF-kappa B pathway by inflammatory stimuli activates Prox1, and both NF-kappa B and Prox1 activate the VEGFR-3 promoter leading to increased receptor expression in lymphatic endothelial cells. This, in turn, enhances the responsiveness of preexisting lymphatic endothelium to VEGFR-3 binding factors, VEGF-C and VEGF-D, ultimately resulting in robust lymphangiogenesis. (Blood. 2010; 115: 418-429)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据